<?xml version="1.0" encoding="UTF-8"?>
<p>Erythromycin is the first macrolide proved to have efficacy in the treatment of rhinovirus and influenza virus [
 <xref rid="B118-pharmaceuticals-13-00096" ref-type="bibr">118</xref>]. On the other hand, clarithromycin and azithromycin have shown higher effectivity towards rhinovirus, respiratory syncytial virus, and influenza virus [
 <xref rid="B118-pharmaceuticals-13-00096" ref-type="bibr">118</xref>,
 <xref rid="B119-pharmaceuticals-13-00096" ref-type="bibr">119</xref>]. In addition, Zika and Ebola viruses have been shown to be inhibited by azithromycin [
 <xref rid="B120-pharmaceuticals-13-00096" ref-type="bibr">120</xref>,
 <xref rid="B121-pharmaceuticals-13-00096" ref-type="bibr">121</xref>]. During the early phase of influenza virus infection, azithromycin has been found to block influenza virus endocytosis into host cells [
 <xref rid="B119-pharmaceuticals-13-00096" ref-type="bibr">119</xref>].
</p>
